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Summary
Elucidating the role(s) of relaxin in women has been greatly hampered by its species specificity. 
Suitable experimental models of relaxin action in women are limited. We established a non-hu-
man primate model of early human pregnancy to study the effects of relaxin in vivo and used 
three well characterized in vitro models of human endometrial function for study of mecha-
nisms involved. Results from these studies clearly demonstrate that relaxin is an import ant 
factor in human endometrium which causes accommodation to and maintenance of early preg-
nancy and uses multiple physiological and biochemical mediators.
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Although it has been more than thirty-five years since the demonstration that relax-
in is a human hormone produced by the corpus luteum of pregnancy (Weiss et al, Sci-
ence 194:948,1976), understanding of the physiological actions of relaxin and the mech-
anisms used in the human reproductive tract are still, to date, quite limited. This is due, 
in large part, to the fact that the sources of production of relaxin, patterns of circulat-
ing concentrations of relaxin , and target organs of relaxin vary markedly from species 
to species. For example, in rodents, relaxin is secreted by the ovary only during second 
half of pregnancy, and a pre-labor surge in circulating relaxin concentrations occurs. 
In horses and rabbits, the placenta is the major source of circulating relaxin, and in dogs 
and cats relaxin secretio n from both the ovary and placenta contribute to circulating 
concentrations. In women, the corpus luteum of the ovary is the only source of circulating 
relaxin; levels become detectable during the late luteal phase of the menstrual cycle and 
will become undetectable if a pregnancy does not ensue. From early pregnancy, circulating 
relaxin levels increase and peak between the eighth and twelfth week of pregnancy and 
then decline slightly and remain relatively constant for the entire duration of pregnancy. 
There is no pre-labor surge as occurs in rodents and pigs. In mice, the major action of 
relaxin is the formation of an intrapubic ligament to enlarge the diameter of the pubis 
allowing parturition. This does not occur in women and non-human primates. Thus, the 
pronounced inter-species differences dictate that improved understanding of the role of 
relaxin in women requires studies in suitable model systems which are representative 
of the human.
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Few in vivo studies of relaxin action in women or in appropriate non-human 
primate models have been performed. We established a non-human primate model 
of early huma n pregnancy using adult, virgin female rhesus monkeys (Macaca mulatta) 
(Goldsmith et al., PNAS 101:4685, 2004). We choose this species since its physiolo-
gy has been extensively studied. It is an Old World monkey and therefore has a men-
strual cycle, which is well characterized and virtually identical to that of women. Pat-
terns of circulating hormones, feedback mechanisms regulating the menstrual cycle, 
and tissue responses of women and female rhesus monkeys are totally alike.
To establish this model, animals were ovariectomized, and, due to lack of steroid 
hormone support, they shed their endometrium within 7 days, as would occur in wom-
en. Animals were implanted with silastic capsules containing crystalline estradiol and 
subsequently capsules containing crystalline progesterone were added, resulting in 
circulating concentrations of estradiol and progesterone which mimic those of the 
follicular and luteal phases. Animals were then randomized to receive either human 
H2 relaxin or vehicle for 21 days, when animals were hysterectomized and tissues 
retained. Circulating relaxin concentrations achieved in this model closely resembled cir-
culating concentrations occurring during early human pregnancy.
In this rhesus monkey in vivo model, a pronounced uterotropic effect of the phys-
iological levels of circulating human relaxin was demonstrated and definitive actions 
of relaxin were observed in various reproductive tract tissues. In the endometrium, 
relaxin significantly increased arteriole number, down regulated progesterone recep-
tor protein expression, and increased numbers of uterine NK cells and macrophag-
es. Relaxin negatively regulated endometrial matrix metalloproteinase expression; 
decreased proMMP-1 and proMMP-3 and increased TIMP-1. These effects demon-
strate that in primate endometrium in vivo, relaxin is uterotropic, angiogenic, regu-
lates resident immune cell number and maintains connective tissue integrity.
In primary human endometrial cell cultures, relaxin stimulated vascular endothelial 
growth factor (VEGF) and inhibited proMMP-1 expression from stromal and secreto-
ry phase epithelial cells. In spontaneously immortalized human endometrial epithelial 
cells, increased intracellular cAMP (the major biochemical effector of relaxin in endo-
metrium) stimulated PGE2 and PGF2alpha was PKA dependent and MAP Kinase 
dependent. In telomerase immortalized human endometrial stromal cells, cAMP stim-
ulated VEGF and Interleukin- 11 were both independent of PKA but MAP Kinase 
dependent.
In women, relaxin is important in the establishment and maintenance of early 
pregnancy and uses multiple physiological and biochemical mediators.
